Boehringer's once-daily pramipexole approved in the EU for Parkinson's
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's new prolonged-release, once-daily tablet formulation of the dopamine agonist Mirapexin/Sifrol (pramipexole) has been granted marketing authorisation by the European Commission for the treatment of the signs and symptoms of early and advanced idiopathic Parkinson's disease.